Dapagliflozin efficacy and safety: a perspective review

被引:42
作者
Anderson, Sarah L. [1 ]
机构
[1] Univ Colorado Anschutz Med Campus, Skaggs Sch Pharm & Pharmaceut Sci, 12850 East Montview Blvd,Room V20-2129, Aurora, CO 80045 USA
关键词
dapagliflozin; hypoglycemic agents; sodium; glucose transporter 2; type 2 diabetes mellitus;
D O I
10.1177/2042098614551938
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Type 2 diabetes mellitus is a prevalent, progressive disease with a need for innovative therapeutic agents to continue to advance disease management. Dapagliflozin is the second agent in a new class of oral antihyperglycemic drugs: sodium-glucose cotransporter 2 (SGLT2) inhibitors. SGLT2 is responsible for the majority of renal glucose reuptake; inhibition of the cotransporter allows for increased renal glucose excretion that consequently leads to reduced plasma glucose levels. Because this mechanism does not require the action of insulin, dapagliflozin rarely causes hypoglycemia and is effective in patients both early and late in the course of their disease. Studies of dapagliflozin have demonstrated efficacy both as monotherapy and in combination with oral antihyperglycemic agents and insulin. Dapagliflozin has been shown to decrease hemoglobin A1c (HbA1c) values 6 mmol/mol (0.5%) to 8 mmol/ mol (0.7%). The most common adverse reactions observed with dapagliflozin in clinical trials were female genital mycotic infections, urinary tract infections, and nasopharyngitis. Dapagliflozin is a new oral agent for type 2 diabetes with short-term efficacy similar to dipeptidyl peptidase 4 inhibitors; its long-term safety and efficacy are unknown.
引用
收藏
页码:242 / 254
页数:13
相关论文
共 37 条
[1]   Standards of Medical Care in Diabetes-2014 [J].
不详 .
DIABETES CARE, 2014, 37 :S14-S80
[2]  
[Anonymous], 1995, Diabetes, V44, P1249
[3]  
[Anonymous], 1995, BMJ, V310, P83
[4]   Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range [J].
Bailey, C. J. ;
Iqbal, N. ;
T'joen, C. ;
List, J. F. .
DIABETES OBESITY & METABOLISM, 2012, 14 (10) :951-959
[5]   Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial [J].
Bailey, Clifford J. ;
Gross, Jorge L. ;
Pieters, Anne ;
Bastien, Arnaud ;
List, James F. .
LANCET, 2010, 375 (9733) :2223-2233
[6]  
Baily CJ, 2011, DIABETOLOGIA S1, V54, pA146
[7]  
Bristol-Myers Squibb Company, 2014, FARX PACK INS
[8]   The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010 [J].
Casagrande, Sarah Stark ;
Fradkin, Judith E. ;
Saydah, Sharon H. ;
Rust, Keith F. ;
Cowie, Catherine C. .
DIABETES CARE, 2013, 36 (08) :2271-2279
[9]   National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants [J].
Danaei, Goodarz ;
Finucane, Mariel M. ;
Lu, Yuan ;
Singh, Gitanjali M. ;
Cowan, Melanie J. ;
Paciorek, Christopher J. ;
Lin, John K. ;
Farzadfar, Farshad ;
Khang, Young-Ho ;
Stevens, Gretchen A. ;
Rao, Mayuree ;
Ali, Mohammed K. ;
Riley, Leanne M. ;
Robinson, Carolyn A. ;
Ezzati, Majid .
LANCET, 2011, 378 (9785) :31-40
[10]   Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes [J].
DeFronzo, Ralph A. ;
Hompesch, Marcus ;
Kasichayanula, Sreeneeranj ;
Liu, Xiaoni ;
Hong, Ying ;
Pfister, Marc ;
Morrow, Linda A. ;
Leslie, Bruce R. ;
Boulton, David W. ;
Ching, Agatha ;
LaCreta, Frank P. ;
Griffen, Steven C. .
DIABETES CARE, 2013, 36 (10) :3169-3176